LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in ...
Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...
AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal investigations.
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
MyChesCo on MSN4h
AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...
Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback